abstract |
The present invention relates to novel synthetic C-glycolipids that selectively induce a Th1-type immune response characterized by enhanced IL-12 secretion and increased dendritic cell activity. Accordingly, the compounds of the present invention are useful directly or as adjuvant for infection, cancer, cytostatic disease, and autoimmune diseases.n n n Th1-type immune response, selective induction, synthetic C-glycolipids, infection, cancer, cytostatic disease, autoimmune diseases |